Access cutting-edge melanoma treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access melanoma specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related melanoma treatment provided free
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Sponsor: ModernaTX, Inc.
Check if you qualify for this melanoma clinical trial in San Francisco, CA
If you're searching for melanoma treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.